# Junta clínica — PT-pseudo_b6db06db35d7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b6db06db35d7",
  "pid": "PT-pseudo_b6db06db35d7",
  "task": 1,
  "psa": 5.2,
  "age": 57,
  "months": 1,
  "pirads": "5",
  "psad": 0.11,
  "psav": 1.38,
  "psap": 3.2,
  "vol": 47.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8199149,
  "medhx": "Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "tamsulosin",
  "notes": "PSA 5.2 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 47 mL. csPCa 0.82.",
  "pmhx": [
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "79 kg",
    "height": "182 cm",
    "bmi": "23.8",
    "bp": "119/89 mmHg",
    "hr": "73 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a recent PSA climb to 5.2 ng/mL alongside a newly identified PI-RADS 5 MRI finding and a previously Positive prior biopsy result."
    },
    {
      "s": "History",
      "t": "A 57-year-old non-smoker who lives independently, this widowed semi-retired musician carries a background of benign prostatic hyperplasia currently treated with tamsulosin. His initial urological workup began in early 2023 when a PSA reading of 2.3 ng/mL was noted, ultimately yielding a Positive prior biopsy. He experiences moderate lower urinary tract complaints, characterized by nocturia occurring twice each night and a diminished stream, yielding an IPSS of 11. Past medical history includes knee osteoarthritis and stable chronic obstructive pulmonary disease, the latter prompting a pulmonary function assessment earlier this month. He walks 45 minutes daily, limits alcohol to roughly 10 units per week, and enjoyed a stable cardiology check in autumn 2024. He explicitly denies bone discomfort, haematuria, or unaccounted weight reduction, citing only the 60-minute train journey to the clinic as a notable daily logistical hurdle."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: DRE confirms a normal examination with a symmetrically enlarged prostate, smooth and firm consistency, and absent nodules or asymmetry. General assessment shows stable vitals (BP 119/89 mmHg, HR 73 bpm) with no abdominal masses or lymphadenopathy. Nutritional status appears adequate, and independent ambulation is noted, accompanied by a mild antalgic gait attributable to established osteoarthritis."
    }
  ],
  "occupation": "musician (semi-retired)",
  "marital": "Widowed",
  "living": "Lives alone",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "10 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 11/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b6db06db35d7
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 57-year-old male
  - PSA: 5.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.38 ng/mL/yr
  - Prior PSA: 3.2 ng/mL
  - Prostate volume: 47.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8199149 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.2 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 47 mL. csPCa 0.82.

Vitals: weight 79 kg, height 182 cm, BMI 23.8, BP 119/89 mmHg, HR 73 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a recent PSA climb to 5.2 ng/mL alongside a newly identified PI-RADS 5 MRI finding and a previously Positive prior biopsy result.

History: A 57-year-old non-smoker who lives independently, this widowed semi-retired musician carries a background of benign prostatic hyperplasia currently treated with tamsulosin. His initial urological workup began in early 2023 when a PSA reading of 2.3 ng/mL was noted, ultimately yielding a Positive prior biopsy. He experiences moderate lower urinary tract complaints, characterized by nocturia occurring twice each night and a diminished stream, yielding an IPSS of 11. Past medical history includes knee osteoarthritis and stable chronic obstructive pulmonary disease, the latter prompting a pulmonary function assessment earlier this month. He walks 45 minutes daily, limits alcohol to roughly 10 units per week, and enjoyed a stable cardiology check in autumn 2024. He explicitly denies bone discomfort, haematuria, or unaccounted weight reduction, citing only the 60-minute train journey to the clinic as a notable daily logistical hurdle.

Physical examination: Per rectum: DRE confirms a normal examination with a symmetrically enlarged prostate, smooth and firm consistency, and absent nodules or asymmetry. General assessment shows stable vitals (BP 119/89 mmHg, HR 73 bpm) with no abdominal masses or lymphadenopathy. Nutritional status appears adequate, and independent ambulation is noted, accompanied by a mild antalgic gait attributable to established osteoarthritis.

Patient info: musician (semi-retired); Widowed; Lives alone.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 10 units / week; exercise Walking 45 min/day; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.10 epistemic (95% band 0.36-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.03: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  2. distance 1.49: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.71: PI-RADS 5, PSA 8.7, PSAD 0.4, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Young patient with high risk disease, should be recommended curative treatment. Biopsy report congruent with MRI, probably caught the index cancer at diagnosis. Highrisk…"

PRECEDENT: BIOPSY (weighted vote 0.70 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines discuss the use of MRI and biopsy in the context of prostate cancer risk stratification. The guideline suggests that a PI-RADS score of 3 or higher mandates a biopsy. "A PI-RADS score of 3 or higher is used to trigger biopsy." This requires the conference to assess if the patient's PI-RADS score meets this threshold.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of biopsy is not settled because the guideline does not account for the patient's prior positive biopsy status. EXPERT-COHORT, the cohort criterion is insufficient because the guideline does not specify how to weigh a prior positive biopsy against current findings.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA trend is significant: if the PSA trend is significant, the guideline suggests further investigation.
laboratory_results - whether the laboratory results indicate a PSA-D is below 0.15ng/mL/cc: if the laboratory results indicate a PSA-D is below 0.15ng/mL/cc, it may be excluded from biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade of the prior biopsy and the significance of the PSA trend as per the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine whether the PSA trend is significant.
  previous_notes (get_previous_notes) -> Determine the grade of the prior biopsy and surveillance status.
  laboratory_results (get_lab_results) -> Determine if the PSA-D is below 0.15 ng/mL/cc.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the PSA trend significant according to the laboratory results?
  Q3. Does the radiology report indicate if the lesion is compared against an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "distinct, hypointense focus within the right mid peripheral zone, spanning 12 x 9 mm."

psa_trend
Is the PSA trend significant according to the laboratory results?: The PSA trend is from "PSA 0.6 (Jan 2023)" rising to "PSA 3.3 (Jan 2024)", and further rising to "PSA 5.2 (Jan 2025)".

previous_notes
What is the grade (Gleason/ISUP) of the prior biopsy?: The grade of the prior biopsy is "low-grade adenocarcinoma (Gleason 3+3)" from "23 Jul 2023". Surveillance status is "The current re-referral follows a PSA climb to 5.2 ng/mL and fresh multiparametric MRI results, warranting specialist reassessment."

laboratory_results
Determine if the PSA-D is below 0.15 ng/mL/cc: The PSA-D is "0.11 ng/mL²" from "21 Dec 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the relevant prior biopsy information.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 finding from the radiology report.
PSA trend is significant, showing a rise from 0.6 to 5.2 ng/mL.

AGAINST sampling this patient now
Prior biopsy result is "low-grade adenocarcinoma (Gleason 3+3)" from previous notes.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 5.20 ng/mL over 3 points spanning 24 months; velocity +2.30 ng/mL per year; doubling time about 8 months.
PROJECTION at 6 months: 6.2 ng/mL, conformal 95% band 1.8-21.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.83), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.70  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: GG 1 ("Gleason 3+3")

RULE THAT FIRED: documented prior grade GG 1 (Gleason 3+3) — carried by documented grade.
PANEL ANSWER: BIOPSY. A documented GG 1 in a man under surveillance is what a confirmatory biopsy is for: the reading urologist re-sampled 3 of the 4 labelled men with a recorded GG 1.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have answered all three moderator questions. The `previous_notes` provided the prior biopsy grade (Gleason 3+3), the `psa_trend` addressed the significance of the PSA rise, and the `radiology_report` addressed the comparison status.

ALIGNMENT WITH THE PANEL
The retrieved finding, the documented prior grade of "low-grade adenocarcinoma (Gleason 3+3)" from the `previous_notes`, aligns directly with the PANEL-PROTOCOL's firing rule, which states that a documented GG 1 in a man under surveillance warrants a biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason/ISUP) of the prior biopsy? Answered by the `previous_notes`: "low-grade adenocarcinoma (Gleason 3+3)".
Q2. Is the PSA trend significant according to the laboratory results? Answered by the `psa_trend` and `laboratory_results` context: the trend is significant, rising from 0.6 to 5.2 ng/mL.
Q3. Does the radiology report indicate if the lesion is compared against an earlier study? Answered by the `radiology_report`: "COMPARISON: new".

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 3+3) carries the most weight because the PANEL-PROTOCOL explicitly states this finding is the rule that fired, indicating it is the primary determinant in this specific context.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with the biopsy based on the panel's conclusion, as the retrieved evidence directly supports the rule that dictated the panel's answer.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

57y male, PSA 5.2, PSAD 0.11, PI-RADS 5, prior biopsy Gleason 3+3. Confirmatory biopsy indicated due to low-grade prior diagnosis and rising PSA. No earlier MRI to compare with, but the finding is clear for tissue sampling. Alternative plan is delaying biopsy for one year and re-sampling.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
